Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited (RDY) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
rdy · stock forecast · 12 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 12 Wall Street analysts in the past 3 months
Buy
12 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $13.31
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $13.20 | ↓ 0.88% |
1-day model range: $13.15–$13.24. Peak: $13.24 (-0.88%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $15 | +9.4% |
| 2028 | $15 | +16.1% |
| 2029 | $16 | +20.8% |
| 2030 | $17 | +23.9% |
| 2031 | — | +26.0% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RDY · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-06-05 | HSBC | Upgrade ↑ | Hold→Buy |
| 2024-11-06 | Barclays | Maintains | Overweight→Overweight |
| 2024-07-30 | Barclays | Maintains | Overweight→Overweight |
| 2024-05-08 | Barclays | Maintains | Overweight→Overweight |
| 2024-01-29 | Barclays | Maintains | Overweight→Overweight |
| 2023-06-01 | Barclays | Maintains | Overweight→Overweight |
| 2022-10-31 | Barclays | Maintains | Overweight→Overweight |
| 2022-10-25 | Barclays | Maintains | Overweight→Overweight |
| 2022-09-12 | Barclays | Maintains | Overweight→Overweight |
| 2022-07-25 | Barclays | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Dr. Reddy's Laboratories Limited (RDY) stock. Of the recent 33 rating actions, 8 were upgrades and 9 were downgrades. 12 analysts currently cover RDY.
Analyst Recommendation Trends
RDY analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$321.2B
↓ 7.8% YoY
Revenue Next Year
$345.1B
↑ 7.4% YoY
EPS This Year
$67.47
EPS Next Year
$60.13
↓ 10.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast RDY EPS of $67.47 for the current fiscal year, based on estimates from 2 analysts. The RDY revenue forecast is $321.2B for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RDY stock forecast is supported by two independent data sources: analyst consensus ratings from 12 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RDY price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The RDY short-term stock prediction for tomorrow is $13.20 (-0.88%). The RDY stock price prediction for 2027 estimates an average of $15. The RDY stock prediction for 2030 projects a range of $16–$17.
Dr. Reddy's Laboratories Limited trades on NYSE under the ticker RDY. The RDY stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
RDY forecast · 8 questionsAccording to 12 Wall Street analysts, the average 12-month RDY price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $13.31.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.